Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer.
Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer.
复制标题
DOI：
10.1007/s10549-012-2183-5
复制
发表时间：
2012-10
影响因子：
3.8
通讯作者：
Li, Christopher I.
中科院分区：
文献类型：
--
作者：
Saltzman, Babette Siebold;Malone, Kathleen E.;McDougall, Jean A.;Daling, Janet R.;Li, Christopher I.
乳腺癌幸存者发生第二原发性非同步对侧乳腺癌（CBC）的风险比女性发生第一原发性乳腺癌（FBC）的风险高60%。然而，关于肿瘤标志物在首次乳腺癌中的表达如何影响CBC风险知之甚少。我们在1996-2008年在华盛顿州西部诊断为首次乳腺癌的20-74岁女性中进行了一项基于人群的巢式病例对照研究，以评估其肿瘤的雌激素受体（ER），孕激素受体（PR）和HER 2-neu（HER 2）表达与CBC风险之间的关系。该研究纳入了482例同时诊断出FBC和CBC的病例，以及1，506名对照女性，这些女性仅被诊断出一次乳腺癌，这是通过我们当地的监测、流行病学和最终结果（SEER）癌症登记处确定的。与FBC为ER+/PR+的女性相比，ER-/PR-优先肿瘤的女性发生CBC的风险增加了1.6倍（95%置信区间（CI）：1.2-2.3）。当通过联合ER/PR/HER 2状态进行评估时，与ER+/HER 2-第一种癌症的女性相比，HER 2过表达（ER-/HER 2+）和三阴性疾病（ER-/PR-/HER 2-）的女性发生CBC的风险分别增加了2.0倍（95% CI：1.1-3.8）和1.4倍（95% CI：0.9-2.3）。除了已知的更积极的BC亚型诊断患者的死亡率较高的风险，在这里，我们观察到，他们也可能有发展CBC的风险增加。
Breast cancer survivors have a 60% higher risk of developing a second primary asynchronous contralateral breast cancer (CBC) compared to women’s risk of developing a first primary breast cancer (FBC). However, little is known about about how expression of tumor markers in first breast cancers influence CBC risk. We conducted a population-based nested case-control study among women 20–74 years of age diagnosed with a first breast cancer between 1996–2008 in western Washington state to evaluate the association between their tumor’s estrogen receptor (ER), progesterone receptor (PR) and HER2-neu (HER2) expression and risk of CBC. The study included 482 cases diagnosed with both a FBC and a CBC and 1,506 control women diagnosed only once with breast cancer identified through our local Surveillance, Epidemiology and End Results (SEER) cancer registry. Compared to women whose FBC was ER+/PR+, those with ER−/PR− first tumors had a 1.6-fold (95% confidence interval (CI): 1.2–2.3) increased risk of developing a CBC. When evaluated by joint ER/PR/HER2 status, compared to women with ER+/HER2− first cancers those with HER2-overexpressing (ER−/HER2+) and triple-negative disease (ER−/PR−/HER2−) had 2.0-fold (95% CI: 1.1–3.8) and 1.4-fold (95% CI: 0.9–2.3) elevated risks of developing CBC, respectively. Beyond the known higher risks of mortality among patients diagnosed with more aggressive BC subtypes, here we observe that they may also have increased risks of developing CBC.
登录
查看更多内容
影响因子：
5.4
作者：
Bernstein, JL;Lapinski, RH;Thompson, WD
通讯作者：
Thompson, WD
影响因子：
3.3
作者：
Hammock, L;Lewis, M;Cohen, C
通讯作者：
Cohen, C
DOI：
10.1093/jnci/djh097
发表时间：
2004-04-07
期刊：
JOURNAL OF THE NATIONAL CANCER INSTITUTE
影响因子：
--
作者：
Swain, SM;Wilson, JW;Wolmark, N
通讯作者：
Wolmark, N
影响因子：
8.8
作者：
通讯作者：
--
影响因子：
10.3
作者：
Kurian, Allison W.;McClure, Laura A.;Clarke, Christina A.
通讯作者：
Clarke, Christina A.